Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of this study is to determine the long term effects of two types of hormonal treatment for advanced prostate cancer (LHRH agonists and the antiandrogen bicalutamide)on the bone mineral density of patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wirral University Teaching Hospital NHS Trust
• Treatments: Androgens; Bicalutamide; Calcium; Calcium, Dietary; Ergocalciferols; Goserelin; Prolactin Release-Inhibiting Factors; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Patients will locally advanced prostate cancer for whom immediate androgen deprivation was indicated

Exclusion Criteria:

• Previous systemic therapy for prostate cancer

• Patients with any illness or medication that would affect bone and mineral metabolism

• Severe hepatic or renal insufficiency